Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT05782270

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Led by China National Center for Cardiovascular Diseases · Updated on 2025-11-18

202

Participants Needed

1

Research Sites

163 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

CONDITIONS

Official Title

Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.
  • No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.
  • Must be able to swallow tablets after the surgery.
Not Eligible

You will not qualify if you...

  • Patients with high bleeding risk (HAS-BLED 2 3).
  • Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time.
  • Emergency surgery.
  • Serum creatinine >130bcmol/L, or significant liver dysfunction (elevated ALT and/or AST).
  • History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding.
  • History of hemorrhagic stroke, or platelet dysfunction.
  • Allergic or with contraindication to any of aspirin, clopidogrel or warfarin.
  • Participated in other clinical trial for drug or device within 30 days.
  • Pregnant or planning to be pregnant.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China, 100037

Actively Recruiting

Loading map...

Research Team

X

Xieraili Tiemuerniyazi, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here